In patients with COVID-19 and moderate-to-severe hypoxemic respiratory failure, high-flow oxygen is as effective as helmet noninvasive ventilation in patients who show PaO2/[FiO2*VAS dyspnea]≥30 and/or PaCO2≥35 mmHg under conventional oxygen, while helmet noninvasive ventilation as applied in the HENIVOT trial may improve clinical outcome among subjects exhibiting PaO2/[FiO2*VAS dyspnea]<30 and/or PaCO2<35 mmHg.
Phenotypes of Patients with COVID-19 Who Have a Positive Clinical Response to Helmet Noninvasive Ventilation
Maggiore, Salvatore Maurizio;
2022-01-01
Abstract
In patients with COVID-19 and moderate-to-severe hypoxemic respiratory failure, high-flow oxygen is as effective as helmet noninvasive ventilation in patients who show PaO2/[FiO2*VAS dyspnea]≥30 and/or PaCO2≥35 mmHg under conventional oxygen, while helmet noninvasive ventilation as applied in the HENIVOT trial may improve clinical outcome among subjects exhibiting PaO2/[FiO2*VAS dyspnea]<30 and/or PaCO2<35 mmHg.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
